Literature DB >> 9922802

Oxidative modification of low-density lipoproteins in atherothrombosis.

P Holvoet1.   

Abstract

Oxidative modification of LDL may occur via mechanisms, which are either dependent or independent of lipid peroxidation. Peroxidation of lipids in LDL, either initiated by radicals or catalysed by myeloperoxidase, results in the generation of aldehydes which substitute lysine residues in the apolipoprotein B-100 moiety and thus in the generation of oxidised LDL. Phospholipase activity, prostaglandin synthesis and platelet adhesion/activation are associated with the release of aldehydes which induce oxidative modifications of LDL in the absence of lipid peroxidation and thus in the generation of malondialdehyde-modified LDL. Recently, we have demonstrated an association between coronary artery disease and increased plasma levels of oxidised LDL. The increase of circulating oxidised LDL is most probably due to backdiffusion of oxidised LDL from the atherosclerotic arterial wall in the blood and is independent of plaque instability. Indeed, plasma levels of oxidised LDL were very similar in patients with stable coronary artery disease and in patients with acute coronary syndromes. Acute coronary syndromes were, however, associated with increased release of malondialdehyde-modified LDL that was independent of necrosis of myocardial cells. Indeed, plasma levels of malondialdehyde-modified LDL were very similar in patients with unstable angina and patients with acute myocardial infarction, in contrast with levels of troponin I which were significantly higher in acute myocardial infarction patients. These data suggest that oxidised LDL is rather a marker of coronary atherosclerosis whereas malondialdehyde-modified LDL is rather a marker of plaque instability and atherothrombosis. At present, in the absence of prospective studies, the causative role of oxidatively modified LDL in atherothrombosis is, however, not established.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9922802

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  6 in total

Review 1.  Anti-oxidant properties of high-density lipoprotein and atherosclerosis.

Authors:  Eugene A Podrez
Journal:  Clin Exp Pharmacol Physiol       Date:  2010-03-30       Impact factor: 2.557

2.  The Number of GT(n) Repeats in the Hemeoxygenase-1 Gene Promoter is Increased in Pediatric Heart Failure but is Unrelated to Renal, Antioxidant and Anti-inflammatory Markers.

Authors:  Sherif Sayed; Naglaa K Idriss; Andrew Blann; Hayam G Sayyed; D M Raafat; Doaa Fouad; M S K Tawfeek
Journal:  Pediatr Cardiol       Date:  2015-03-31       Impact factor: 1.655

3.  Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study.

Authors:  Francisco J Martinez-Martin; Alicia Macias-Batista; Cristina Comi-Diaz; Herminia Rodriguez-Rosas; Paula Soriano-Perera; Pablo Pedrianes-Martin
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 4.  Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes.

Authors:  Valentina Loria; Ilaria Dato; Francesca Graziani; Luigi M Biasucci
Journal:  Mediators Inflamm       Date:  2008       Impact factor: 4.711

5.  Biomarkers in Acute Coronary Syndrome.

Authors:  Valentina Loria; Milena Leo; Gina Biasillo; Ilaria Dato; Luigi M Biasucci
Journal:  Biomark Insights       Date:  2008-11-05

6.  Unique antibody responses to malondialdehyde-acetaldehyde (MAA)-protein adducts predict coronary artery disease.

Authors:  Daniel R Anderson; Michael J Duryee; Scott W Shurmur; John Y Um; Walter D Bussey; Carlos D Hunter; Robert P Garvin; Harlan R Sayles; Ted R Mikuls; Lynell W Klassen; Geoffrey M Thiele
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.